Does three-dimensional imaging offer a financial benefit for treating maxillary molars with furcation involvement? – A pilot clinical case series
Article first published online: 21 OCT 2011
© 2011 John Wiley & Sons A/S
Clinical Oral Implants Research
Volume 23, Issue 3, pages 351–358, March 2012
How to Cite
- Issue published online: 13 FEB 2012
- Article first published online: 21 OCT 2011
- Manuscript Accepted: 25 AUG 2011
- 3D imaging;
- cone beam computed tomography;
- cost benefit analysis;
- maxillary furcation surgery
To assess the financial benefit of cone beam computed tomography (CBCT) for the treatment options of maxillary molars including periodontal surgery and extraction followed by implant placement.
Material and methods
Twelve patients with generalized chronic periodontitis were recruited, and CBCT was performed in maxillary molars (n = 22) with clinical furcation involvement and increased probing pocket depths. Treatment recommendations were either based on conventional periodontal diagnostics (clinical examinations and periapical radiographs), or based on the additional CBCT data. Clinical recommendations comprised a minimal (e.g. supportive periodontal treatment) and a maximal invasive therapy (e.g. extraction and implant placement), and these were compared with CBCT-based recommendations. According to the Swiss dental tariff structure, the probabilities of saving costs or time, and the numbers needed to treat were analysed with an empirical cumulative distribution function.
Average cost reduction from CBCT amounted to CHF 915 ± 1470 and saved 136 ± 217 min. Greatest reductions were found with maximal invasive clinically based treatment decisions (CHF 1566 ± 1840), particularly for second molars (CHF 2485 ± 2226). To compensate CBCT costs, 1.7 subjects were needed to treat to at least break even.
Data from CBCT facilitated a reduction in treatment costs and time for periodontally involved maxillary molars in Switzerland. Based on these cost analyses, however, CBCT as additional diagnostic measure is justified only when more invasive therapies are planned.